Mutated recombinant human glucagon-like peptide-1 protects SH-SY5Y cells from apoptosis induced by amyloid-β peptide (1-42)

Neuroscience Letters

Volumn 444, Issue 3, 2008, Pages 217-221

  Qin, Zhenxia ^a   Sun, Zhongwei ^a   Huang, Jing ^b   Hu, Yinghe ^a   Wu, Zirong ^b   Mei, Bing ^a  

^a B326 Science Building   (China)

^b EAST CHINA NORMAL UNIVERSITY   (China)

Author keywords

A 1 42; Alzheimer's disease; Apoptosis; mGLP 1; SH SY5Y cells

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN (1 42); CALCIUM; GLUCAGON LIKE PEPTIDE 1; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOMETRY; GENETIC RECOMBINATION; HUMAN; MUTAGENESIS; NERVE CELL; PRIORITY JOURNAL;

AMYLOID BETA-PROTEIN; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CALCIUM; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIC AMP; GLUCAGON-LIKE PEPTIDE 1; HUMANS; MUTATION; NEURONS; PEPTIDE FRAGMENTS; RECOMBINANT PROTEINS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 52249112474     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2008.08.047     Document Type: Article

References (31)

1. Antonsson B. Bax and other pro-apoptotic Bcl-2 family "killer-proteins" and their victim the mitochondrion. Cell Tissue Res. 306 (2001) 347-361
2. Arispe N., Rojas E., and Pollard H.B. Alzheimer disease amyloid beta protein forms calcium channels in bilayer membranes: blockade by tromethamine and aluminum. Proc. Natl. Acad. Sci. U.S.A. 90 (1993) 567-571
3. Arulmozhi D.K., and Portha B. GLP-1 based therapy for type 2 diabetes. Eur. J. Pharm. Sci. 28 (2006) 96-108
4. Blasko I., Wagner M., Whitaker N., Grubeck-Loebenstein B., and Jansen-Durr P. The amyloid beta peptide abeta (25-35) induces apoptosis independent of p53. FEBS Lett. 470 (2000) 221-225
5. Chipuk J.E., Kuwana T., Bouchier-Hayes L., Droin N.M., Newmeyer D.D., Schuler M., and Green D.R. Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science 303 (2004) 1010-1014
6. Chumakov P.M. Function of the p53 gene: choice between life and death. Biochemistry (Moscow) 65 (2000) 28-40
7. Ekinci F.J., Linsley M.D., and Shea T.B. Beta-amyloid-induced calcium influx induces apoptosis in culture by oxidative stress rather than tau phosphorylation. Brain Res. Mol. Brain Res. 76 (2000) 389-395
8. Ferris C.D., Cameron A.M., Bredt D.S., Huganir R.L., and Snyder S.H. Inositol 1,4,5-trisphosphate receptor is phosphorylated by cyclic AMP-dependent protein kinase at serines 1755 and 1589. Biochem. Biophys. Res. Commun. 175 (1991) 192-198
9. 2+ release through ryanodine and inositol 1,4,5-triphosphate receptors in the neurotoxic effects induced by the amyloid-beta peptide. J. Neurosci. Res. 76 (2004) 872-880
10. Green B.D., Liu H.K., McCluskey J.T., Duffy N.A., O'Harte F.P., McClenaghan N.H., and Flatt P.R. Function of a long-term, GLP-1-treated, insulin-secreting cell line is improved by preventing DPP IV-mediated degradation of GLP-1. Diabetes Obes. Metab. 7 (2005) 563-569
11. Hardy J., and Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297 (2002) 353-356
12. Hooper C., Meimaridou E., Tavassoli M., Melino G., Lovestone S., and Killick R. p53 is upregulated in Alzheimer's disease and induces tau phosphorylation in HEK293a cells. Neurosci. Lett. 418 (2007) 34-37
13. J. Huang, Z. R. Wu, J. Xu, M. F. Jin, Y. L. Wu, J. Li, Preparation and application of one human glucagon-like peptide-1 analogue. Chinese Patent: Application number 200610024355.X(2006), Publication number CN1982336(2007). http://www.soopat.com/Patent/Content/200610024355.html.
14. John H., Maronde E., Forssmann W.G., Meyer M., and Adermann K. N-terminal acetylation protects glucagon-like peptide GLP-1-(7-34)-amide from DPP-IV-mediated degradation retaining cAMP- and insulin-releasing capacity. Eur. J. Med. Res. 13 (2008) 73-78
15. Kitamura Y., Shimohama S., Kamoshima W., Matsuoka Y., Nomura Y., and Taniguchi T. Changes of p53 in the brains of patients with Alzheimer's disease. Biochem. Biophys. Res. Commun. 232 (1997) 418-421
16. Klein W.L., Krafft G.A., and Finch C.E. Targeting small Abeta oligomers: the solution to an Alzheimer's disease conundrum?. Trends Neurosci. 24 (2001) 219-224
17. Knudsen L.B., and Pridal L. Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1-(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor. Eur. J. Pharmacol. 318 (1996) 429-435
18. LaFerla F.M. Calcium dyshomeostasis and intracellular signalling in Alzheimer's disease. Nat. Rev. Neurosci. 3 (2002) 862-872
19. Mattson M.P. Pathways towards and away from Alzheimer's disease. Nature 430 (2004) 631-639
20. Parihar M.S., and Hemnani T. Alzheimer's disease pathogenesis and therapeutic interventions. J. Clin. Neurosci. 11 (2004) 456-467
21. Perry T., and Greig N.H. The glucagon-like peptides: a double-edged therapeutic sword?. Trends Pharmacol. Sci. 24 (2003) 377-383
22. Perry T., and Greig N.H. The glucagon-like peptides: a new genre in therapeutic targets for intervention in Alzheimer's disease. J. Alzheimer's Dis. 4 (2002) 487-496
23. Perry T., Lahiri D.K., Chen D., Zhou J., Shaw K.T., Egan J.M., and Greig N.H. A novel neurotrophic property of glucagon-like peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells. J. Pharmacol. Exp. Ther. 300 (2002) 958-966
24. Perry T., Lahiri D.K., Sambamurti K., Chen D., Mattson M.P., Egan J.M., and Greig N.H. Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron. J. Neurosci. Res. 72 (2003) 603-612
25. 2+ release from platelet internal membranes is regulated by differential phosphorylation. Biochemistry 35 (1996) 6865-6871
26. Schmidt T., Korner K., Karsunky H., Korsmeyer S., Muller R., and Moroy T. The activity of the murine Bax promoter is regulated by Sp1/3 and E-box binding proteins but not by p53. Cell Death Differ. 6 (1999) 873-882
27. Selkoe D.J. Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. 81 (2001) 741-766
28. Vahl T.P., Paty B.W., Fuller B.D., Prigeon R.L., and D'Alessio D.A. Effects of GLP-1-(7-36)NH2, GLP-1-(7-37), and GLP-1- (9-36)NH2 on intravenous glucose tolerance and glucose-induced insulin secretion in healthy humans. J. Clin. Endocrinol. Metab. 88 (2003) 1772-1779
29. van Engeland M., Nieland L.J., Ramaekers F.C., Schutte B., and Reutelingsperger C.P. Annexin V-affinity assay: a review on an apoptosis detection system based on phosphatidylserine exposure. Cytometry 31 (1998) 1-9
30. Wirths O., Multhaup G., and Bayer T.A. A modified beta-amyloid hypothesis: intraneuronal accumulation of the beta-amyloid peptide-the first step of a fatal cascade. J. Neurochem. 91 (2004) 513-520
31. Younkin S.G. The role of A beta 42 in Alzheimer's disease. J. Physiol. (Paris) 92 (1998) 289-292